Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesAdjuvant chemotherapy for high-risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration
The Journal of Urology, 08/19/09
Hellenthal NJ et al. – In a study to determine the incidence of adjuvant chemotherapy in high-risk pts and the ensuing effect on overall and cancer specific survival, it was reported that adjuvant chemotherapy is infrequently used to treat high-risk upper tract urothelial carcinoma after nephroureterectomy. Despite this finding, it appears that adjuvant chemotherapy confers minimal impact on overall or cancer-specific survival in this group.
Methods- 1390 pts were identified who underwent nephroureterectomy for nonmetastatic upper tract urothelial carcinoma.
- 542 (39%) of 1390 cases were classified as high risk (pT3N0, pT4N0 and/or lymph node-positive).
- Pts were divided into 2 groups, including those who did and did not receive adjuvant chemotherapy, and stratified by gender, age group, performance status, and tumor grade and stage.
- Cox proportional hazard modeling and Kaplan-Meier analysis were used to determine overall and cancer specific survival.
- Of high-risk pts, 121 (22%) received adjuvant chemotherapy.
- Adjuvant chemotherapy was more commonly administered in the context of increased tumor grade and stage.
- Median survival in the cohort was 24 mos (range 0 to 231).
- There was no significant difference in overall or cancer specific survival between pts who did and did not receive adjuvant chemotherapy.
- Age, performance status, and tumor grade and stage were significant predictors of overall and cancer specific survival.
Related Articles
Diagnosis and Treatment of Bladder Cancer
American Family Physician, 10/01/09
Relevance Score: 87%
The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion the prognostic contribution of related molecular markers
Histopathology, 11/11/09
Relevance Score: 80%
Altered fractionation and adjuvant chemotherapy for head and neck squamous cell carcinoma
Head & Neck, 11/09/09
Relevance Score: 80%
Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients
Human Pathology, 10/08/09
Relevance Score: 80%
Expression of Stathmin in Localized Upper Urinary Tract Urothelial Carcinoma: Correlations With Prognosis
Urology, 10/06/09
Relevance Score: 80%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial)
Annals of Oncology, 12/04/09
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
Annals of Oncology, 12/04/09
Three-dimensional (3D) Overlay Culture Models of Human Breast Cancer Reveal a Critical Sensitivity to MEK Inhibitors
Journal of Pharmacology and Experimental Therapeutics, 12/04/09
Sponsor
Article Search
Sponsor